Cystic fibrosis (CF) — Trikafta era

What changes during this transition

Cystic fibrosis is an autosomal recessive disorder caused by biallelic mutations in CFTR (cystic fibrosis transmembrane conductance regulator) on chromosome 7q31.2, encoding a cAMP-regulated chloride/bicarbonate channel. Loss of CFTR function produces defective epithelial chloride and bicarbonate transport, which produces thick viscous secretions across lung, pancreas, intestine, biliary tract, sweat glands, and reproductive tract. Roughly 30,000 patients in the US, incidence ~1 in 2,500-3,500 in Northern European populations (founder effect), with over 2,000 identified CFTR mutations grouped into six functional classes by mechanism (F508del is the most common). Manifestations are multi-organ: PULMONARY — chronic and recurrent infection (Pseudomonas, Burkholderia, Staphylococcus, Mycobacterium abscessus, Aspergillus), chronic inflammation, bronchiectasis, progressive FEV1 decline, historically the leading mortality cause; PANCREATIC — exocrine insufficiency with malabsorption and steatorrhea in ~85% of patients, pancreatic enzyme replacement therapy (PERT) required, plus CF-related diabetes (CFRD), the leading endocrinopathy in CF, structurally distinct from T1DM and T2DM, affecting ~50% of adults, insulin-managed; HEPATOBILIARY — cirrhosis, portal hypertension, gallstones; GI — DIOS (distal intestinal obstruction syndrome), constipation, meconium ileus in newborns; NUTRITIONAL — historically failure to thrive with high-calorie/high-fat diet, but post-Trikafta this picture is shifting toward weight management as a new concern; SINUS — chronic rhinosinusitis with polyps; MUSCULOSKELETAL — osteoporosis; REPRODUCTIVE — congenital bilateral absence of the vas deferens (CBAVD) in nearly all males with CF, producing obstructive infertility navigable through ICSI; reduced but possible female fertility with pregnancy planning increasingly common in the modern era. Diagnosis: universal newborn screening in the US, sweat chloride test (>60 mmol/L positive, 30-59 intermediate), CFTR mutation analysis. Care is delivered through comprehensive multidisciplinary CF centers tracked through the CF Foundation patient registry. STANDARD OF CARE HAS BEEN TRANSFORMED BY CFTR MODULATORS. Ivacaftor (Kalydeco, Vertex) was FDA-approved in 2012 as a potentiator for G551D and other gating mutations, opening the modulator era. Lumacaftor/ivacaftor (Orkambi, 2015) and tezacaftor/ivacaftor (Symdeko, 2018) followed for F508del homozygous patients. The paradigm shift arrived in October 2019 with elexacaftor/tezacaftor/ivacaftor (TRIKAFTA, Vertex) — a triple-combination 'highly effective modulator therapy' that covers roughly 90% of the CF population (F508del heterozygous and homozygous). Phase 3 trials showed dramatic FEV1 improvement (+14 percentage points), dramatic sweat chloride reduction, falling pulmonary exacerbation rates, quality-of-life gains, many patients delisted from lung transplant, and increasing pregnancies — a fundamental reshaping of CF prognosis in a single generation, with adults now living into their 50s and 60s in numbers that were not possible in the 1990s. Other care remains foundational: airway clearance therapies (chest physiotherapy, vest, flutter, autogenic drainage); inhaled therapies including dornase alpha (Pulmozyme, FDA-approved 1993 — a recombinant DNase that cleaves DNA released from neutrophils accumulating in viscous CF mucus; this is the canonical peptide-related CF therapy and the first FDA-approved CF-specific drug, predating the modulator era by two decades), hypertonic saline 7%, and inhaled antibiotics (tobramycin, aztreonam, colistin); oral antibiotics for exacerbations; PERT (lipase + protease + amylase with meals); fat-soluble vitamin supplementation (A, D, E, K); insulin for CFRD; and lung transplantation for end-stage disease (decreasing need post-Trikafta). CFRD management follows ADA and CF Foundation joint guidelines — insulin, not oral agents, and a complications profile distinct from T1/T2 DM. Nutrition and psychosocial support are lifelong. Patient advocacy and research: Cystic Fibrosis Foundation (cff.org), CF Network international, transplant center networks. Editorial substrate framing: CF reaches the peptide conversation through several distinct channels that the substrate addresses honestly. Community 'gut healing' framing of BPC-157 lands on a malabsorptive, PERT-dependent population with a channelopathy that is not a healing problem and does not respond mechanistically to gastric-juice-derived pentadecapeptides. NMN reaches CF through the general-aging channel, which post-Trikafta is no longer a categorical mismatch — but introduces Trikafta CYP3A interaction concerns and CFRD complexity that the general-aging substrate doesn't carry. GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) sit at the intersection of legitimate historical CF growth-failure use of somatropin under pediatric endocrinology and post-Trikafta body-composition inversion — community GH-axis stacking is over-amplified relative to the standard-of-care option and carries CFRD-diabetogenic concerns. Semaglutide is the genuinely novel post-Trikafta case: adults with CF who historically carried undernutrition are now sometimes overweight, GLP-1 use in CF is emerging off-label, and the unresolved questions around PERT-interaction, CFRD-structural-distinctness, and baseline pancreatic disease make this a CF-center-plus-endocrinology joint decision rather than a weight-loss-clinic prescription. None of these community peptides are elevated on the discovery hub for CF — the substrate exists for /ask honesty when users probe; dornase alpha is named in this overview as the legitimate peptide-related CF therapy because that is what it is. Modern CF patients face a transformed prognosis with rapidly evolving therapeutic decisions — fertility planning including CBAVD-navigation through ICSI, adult-onset complications never reached historically, post-Trikafta weight and metabolic shifts, transplant decisions, CFRD diagnoses in adolescence, and the psychological burden of a disease whose trajectory has changed in one generation. The CF center and the multidisciplinary team remain the load-bearing anchor for every decision; community peptide protocols are not an appropriate parallel track. Seventieth deliberate non-elevation of community peptides.